N
Google TrendANNA BONDAR (200+) — October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:anna bondar200+natanael cano100+green card500+power outage near me10000+india2000+sony playstation1000+loki100+hubert hurkacz200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Triple hormone receptor a" (30 stories)

Top Headline Story

Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
Lead StorySTATgeneral
Jun 6

Triple hormone receptors, a monthly obesity drug, and a bittersweet ending

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPWms5Y2VlYkFrcUdmVUQyenJscllJS3dGU3d6dGxxTWRKOG9JWk80WGpwU3FuWlhObGk2eUJncTNUYU81Y0xoVHg0V2l1am9VVmVJZG5hNThFVTdUdVh4ZkJfdjFJQUFFQW1zLUxzZ1FNSUVOX1k1TkE0Ymo5SFlRUzNvZEQ0VGZYYXZmRmZKRFJnUQ?oc=5" target="_blank">Triple hormone receptors, a monthly obesity drug, and a bittersweet ending</a>  <font color="#6f6f6f">STAT</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
200+23m ago

anna bondar

October 11, 2026: Lilli Tagger vs Nikola Bartunkova: Set 1 Winner Prediction Market

Filter stories
100+23m ago

natanael cano

Padres de Natanael Cano rompen el silencio tras retiro del cantante: "Es por el bien de nuestro hijo"

Filter stories
500+33m ago

green card

Vance says Microsoft replaced laid-off workers with foreign hires. Here’s what the visa data shows

Filter stories
10000+33m ago

power outage near me

LIVE | Atlanta weather: Power outages, tree damage remain as storm threat moves east

Filter stories

Search Results for "Triple hormone receptor a"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity
PR Newswiregeneral

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxOOXNfcnRyMG85bG1wdExwXzRpdUxYeEx4ODBaQU54OTEweG9lWWx4Tm9jczBNcWtOVjBhTFl3TlpPMU9Nd05QdXZseHZTRl91TTZmVWFuc29ncEt0S0NfaE92dXhaM1ZSZmJLMUVTR2JvYWdwRkJ1YXlzbHdrMzYycVlCaEFCUkNQYll1aVRyNHN1X2VaOGhheG84VnVkZ1ZvN1E4ZzgwcHVQdHRsZDFOTlp0WEpvTjhyM2N4cHpTVF9sdDFwTVNVd3FrSzlpdjRzVmpnTDhwUHVDbkhzR0hBVUtfeUNIQjBCUnVQcXBTVUFJLU1jOHVZdDcxWDNkRW8?oc=5" target="_blank">Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
Eli Lillytech

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPVDhGeGxDUkYtaFFJeVVpNFdkNk44SzdvejNHQ0Y5OGp4czBjUV9WYncyc3lQOUJXbHFnS182SmhHVzF1Njd0d3YyV2dJeUx2cGxJWmt1U1hsWG9WMVJHOGFXMXVJelNOZ24ycTZEQ3FTcUxNS1NfQ1RzVkcwZ1JFRHVIdDllUl9ia24wUjJ0WkpocHEzR0NHMHpmWnM3aDhxdVdYZmMxNWdHVF9tNDdMVXpCd1lnMzZ3TUhvc3RXbkdpRnc?oc=5" target="_blank">Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial</a>  <font color="#6f6f6f">Eli Lilly</font>

Read Full StoryMore like this
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Br
CancerNetworkgeneral

119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Br

<a href="https://news.google.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?oc=5" target="_blank">119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Br</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Invasive Apocrine Carcinoma in a Young Female With Triple Hormone Receptor Positivity: A Case Report
Cureusworld

Invasive Apocrine Carcinoma in a Young Female With Triple Hormone Receptor Positivity: A Case Report

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNcGdoSmthVm5IWEJvS2xCSmFUSXR4czRiY3VaS2ZXaU42eTNsb1JDaEd1OGV3dzlsRDJTWV80ekZ3bUV5VGpLNWtVV3gzak5aV3Vjd25MZmtKaGFBMnBXelY3T3VBaEliTzZiNjE1UVAwX2wyeU1NMVBFS0pqWWRaMEtfUm02R2pwb2J1d1ZjSGVYS2l6RF9ZR2JMLTRKMzhNWEhWRDRKclFHQ1M2RmU4Y1RaNC1vUkJFV2tHblZTX3VUOG0xV1RpMVFhMmNFZXJZU1A4YQ?oc=5" target="_blank">Invasive Apocrine Carcinoma in a Young Female With Triple Hormone Receptor Positivity: A Case Report</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Eli Lilly’s New Weight-Loss Treatment Shows Promising Results
WSJgeneral

Eli Lilly’s New Weight-Loss Treatment Shows Promising Results

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOSFVUUE93aC1QcEVjeE03MHFXUzZPd25kSnZKY1NGUGNrblZ3aEdILUMtWWhTeXdDN2tuTHIxNHg3YWs2Rjlsbm5XZGVoYjc0MmhLZjRNVlJvSmZacFhrdE9CTi14ZHIyZWhlT1F4OWR2SnlHXzRVM09JQ1pxYUdQWFFJZWtLZlJTUlNvNS0xZWRDcHFSa09HMXVrVmxHZEgzLTNhNnhR?oc=5" target="_blank">Eli Lilly’s New Weight-Loss Treatment Shows Promising Results</a>  <font color="#6f6f6f">WSJ</font>

Read Full StoryMore like this
Lilly’s triple agonist shows bariatric surgery–like weight loss results
BioSpacegeneral

Lilly’s triple agonist shows bariatric surgery–like weight loss results

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPc3dPZEo4cy1NTGF5RUhqLWRBSHlQa0UzUTVBdFZRZmxXRVM0NFJKNFAxUFlkRFBIYWVMUWNRbG1rUkVuYXkwanJlaEs2YUVtWElLZFRKMFpBODlkQXZTUnlaVktiay04XzNORzQxOWxlV2pSSEpEbjZsX09zRnI2VjlpNzZ4Uk8zRFBuanRDZm1ZY3VtSHRlaENlSWZaUEZSaDVsaGNNa2x0VkVHZzdTRXVn?oc=5" target="_blank">Lilly’s triple agonist shows bariatric surgery–like weight loss results</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Triple hormone receptor agonist improves glycaemic control and bodyweight reduction in T2D
Medical Republicgeneral

Triple hormone receptor agonist improves glycaemic control and bodyweight reduction in T2D

<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxQMmJWM1NKNFhtT0VrMmpMeWgzUG9Yb3N2bUFDbzJ5UGg4MVYxdm1jRmpGaTIxd1NqUW9kdFk1Vk94aHNWWHVaejlDVG9VWHU2T3ZWNVpoNHF1Q3dZUThSTVBHVWIyTGhnS0Q0UDNHTlJXZUtHbnlxb0puRFN5UUFxemQyUGV0TXlPbHIzRU9jb0hsOWF4RjlCSDhfeEN5TGc1QXpVc3hWN0JVZUV6VlI2aHZaTTBjYl9GUW04M21KMk1QYXYyMU9IcEJ0dHg?oc=5" target="_blank">Triple hormone receptor agonist improves glycaemic control and bodyweight reduction in T2D</a>  <font color="#6f6f6f">Medical Republic</font>

Read Full StoryMore like this
What Is a GLP-3? GLP-3 Drugs, Explained
Rotech

What Is a GLP-3? GLP-3 Drugs, Explained

<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE9oR3NwTGVERUJOVkhuLXlidFFLRWxMVjlVNEc0ejI2cVlvN2pHUE9ob3drQzZkQ2o2UWJTcmt4VUZ0eEwtUDFmSHpYUU8yd1F0S0U4bA?oc=5" target="_blank">What Is a GLP-3? GLP-3 Drugs, Explained</a>  <font color="#6f6f6f">Ro</font>

Read Full StoryMore like this
Dual vs. Triple Agonist Weight Loss Drugs: Key Differences
HealthCentralgeneral

Dual vs. Triple Agonist Weight Loss Drugs: Key Differences

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOUkF1MEhuU3FydHViQW5TVlRtUU53S3VoM2NISXdyMjUxelJWSTlySUlkS1dFZlVxaTdZMDRlN2dFY2Rnd0ZkR2c3TlBRdGFONlVKTmZkRFdfRzJodklpVE5sblRyMWRYbTdHZjh4Ri1rU09sRFJtUGhaU0dSY3BieWtKYmNTTmoyRF9FM0xNU0t2WnVHX21PY1dWSFJNYlhrbUQtWEdrMS1tMFZMbjZMem1kZ3VhUnRLeWc?oc=5" target="_blank">Dual vs. Triple Agonist Weight Loss Drugs: Key Differences</a>  <font color="#6f6f6f">HealthCentral</font>

Read Full StoryMore like this
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
NEJMgeneral

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9QR1RBcUI5bGdZbzBYaXFmQTF1cXFqM2N1TnlQMjJLMzBxRl9JMzhWVGJJWFJZdFNUUEdQbjRMRVhhZEE1Zk9PWWZWX1ljOTBQRGpmXzB1RVF5YzBpdnRTYw?oc=5" target="_blank">Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer
Natureworld

Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5YUFhMaFdNcC1WSXlnTUJuZDRTTUZLUUVmSU1TWHFjRUJUUTd0Znk2RkVQQWp4aS1FOEVnd2wxUTJnWU5wZG81MGNnSzhQbEZ2YUlxVkZJY2lJeFYwTTdr?oc=5" target="_blank">Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
128 TroFuse-032: a Phase 3, Randomized Study of Pembrolizumab Plus Sacituzumab Tirumotecan or Chemotherapy Followed by Pembrolizumab Plus Chemotherapy for Early-Stage Triple-Negative Breast Cancer or Hormone Receptor-Low–Positive/Human
CancerNetworkgeneral

128 TroFuse-032: a Phase 3, Randomized Study of Pembrolizumab Plus Sacituzumab Tirumotecan or Chemotherapy Followed by Pembrolizumab Plus Chemotherapy for Early-Stage Triple-Negative Breast Cancer or Hormone Receptor-Low–Positive/Human

<a href="https://news.google.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?oc=5" target="_blank">128 TroFuse-032: a Phase 3, Randomized Study of Pembrolizumab Plus Sacituzumab Tirumotecan or Chemotherapy Followed by Pembrolizumab Plus Chemotherapy for Early-Stage Triple-Negative Breast Cancer or Hormone Receptor-Low–Positive/Human</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
New triple-action diabetes jab delivers impressive blood sugar and weight-loss results
The News Internationalgeneral

New triple-action diabetes jab delivers impressive blood sugar and weight-loss results

<a href="https://news.google.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?oc=5" target="_blank">New triple-action diabetes jab delivers impressive blood sugar and weight-loss results</a>  <font color="#6f6f6f">The News International</font>

Read Full StoryMore like this
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
Natureworld

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA2dWdzek5DR3VPSVFFVlZxdVpROFJpZzNoNWlNR0huZVhIX0Vubmt3bFl5MXVRVW5JaDN2QkVmc2dEMVRjSWxHWUFLZlpWZWVsUEF5b0RYakJmMkpkN2U0?oc=5" target="_blank">Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges
BioSpacegeneral

Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges

<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQNUVJUlctdUlLQmhiY2dRRXpYWkZMRXhxNERpcFAzTnR3Zmp1RGFDVmFic0tZVVJxWjd5WkZ6NVZMaFlJSVotckxid3NHdWFLUmx3TlNuQ2c4YzhyQ1pCbWdoS1VJWURiMmw0VUN5bUgtbGdYdDNiSzR4ajZGOUw3alFOUkwwRXNpeVUwZF9fVDJ6WUw3THFrTFRPR0JnT0NTX0F5Q0VETVdsZm9zLTl4VHlLV0k5ajdJQlJSX1lSRlFLWUt1cHQxa2xfNlNVMThFMW5tUw?oc=5" target="_blank">Lilly’s Retatrutide Scores Triple Trial Triumph With 26% Weight Loss, But New Safety Signal Emerges</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Deciding Between Hormone Receptor Positive and Triple Negative in ER-Low Breast Cancer
Cancer Nursing Todaygeneral

Deciding Between Hormone Receptor Positive and Triple Negative in ER-Low Breast Cancer

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQVUstdU5vV0Zuc3k1ZGVIQnhkU055REl5SHl4OXBjMWpzS2lQbzRPeXVLTUF2TktyZFBPUDlmS3lpaDR5OGZTQ1dubzg4bk1tNG9ZRjN3dmF6aHhlUVV3dnhIM0RYYUlBT0hrY3hRNG5VVU5TeGpQbmlGN082Tno2d21ac0FIa01MczRzMXRmaTNIY3kwRG1aQkQxUy1vWlZkSkQ0N2VEQmtoTG5IUFBCR3NtU1oybGhTUnhoRUlCdUVwYWtG?oc=5" target="_blank">Deciding Between Hormone Receptor Positive and Triple Negative in ER-Low Breast Cancer</a>  <font color="#6f6f6f">Cancer Nursing Today</font>

Read Full StoryMore like this
Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery
UCHealthgeneral

Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery

<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE0wOW5qV3QxOXZZLWJ5c1JMTGNsN1FpZ1VBSHkxWlBiMzA3Mk0zR0l2ZHdlTUhab0pjYVlUdzVkM040Smg4TTlGYlVLelo3SllzR1VPdzJPTUxhUmdjYTcwMHdSTHRGZjh2Qko4?oc=5" target="_blank">Retatrutide, the newest weight-loss drug, helped people lose 30% of body weight, on par with weight-loss surgery</a>  <font color="#6f6f6f">UCHealth</font>

Read Full StoryMore like this
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
PR Newswiregeneral

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxNYUdsRUpvMk5OV3V5WmR4dU1hekRONUhnX1lBeGYwLThCY0hyakpSWE9LSVo3UkttU1p5ZHpCLVVVOEdKOFZqMjVFZnBvQkw1Tzc2NUFGYnljdmEtMWthWTN4cTlXUHBZcjhWMERMTjFHN2diLUl3MDQ0cXViRzYxXzBOYTR2Sm5NV1RHa1V3RkdLUFBtYUdqb3Y5SFpjR0JrSXhlWmxCcGtnWFlIeU1VaUR1SFotWGx1RnpKekdmWWUyU19nN01DLS1IT2pNT1Z4YzdqV1oxQU1ua3BPVHdnRzVDdWp6d3U2?oc=5" target="_blank">Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy
Naturegeneral

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBrblBnd2pwWm5YN2RsN2h1ZkkwU3d1b25oT1NwY3k1ajBsVGxkNlZyWmwwTC02NFVlNzQyR013N29EaTBMUjRRWW54aHpjdUVwbFNuQ0RheVdXaEhJbEdn?oc=5" target="_blank">Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | Signal Transduction and Targeted Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Naturegeneral

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXeUpiMnpnaC0wRl92b21RMGttUzd0WFQtWU1WajZ0SF9LT05uVG0zY1RHQnFrVTF5U21jS0pKU3R1c1hZdGhIcUtxdnpSNFlUclJXQWJfOUpHakNNQUo4?oc=5" target="_blank">Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
TRIUMPH-1 Trial Shows Potential for Retatrutide As a Treatment for Obesity
DocWireNewsgeneral

TRIUMPH-1 Trial Shows Potential for Retatrutide As a Treatment for Obesity

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNU2ZGSUo3WDM2YzhfS3hkVDZqVnZfQjJzSXpOTzY5WWw4dlN1RFlrZDVNVGFDOGU2QktrU2lmV2pNS1g0dzMyMVUzZFIyVTd0Q0hrZm9PODNucnlnOGxqajYxVFQ5b05LSmpFU19INEtWdy0xem1icWNmaUpTX1lreGhZTEFrVUhlcDZ1UWNhLW1NSWE0Q2piUS1UOTdrUWtRUkN0c09odEZVeWc?oc=5" target="_blank">TRIUMPH-1 Trial Shows Potential for Retatrutide As a Treatment for Obesity</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Retatrutide Delivers Unprecedented Weight Loss in Phase 3
Medscapeworld

Retatrutide Delivers Unprecedented Weight Loss in Phase 3

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPRTNfbXhvUE9fNXhLOFVFS1ZFU2hlbnVlUENUTV9BTzN6cll3aXNrQ3hPU1NmRXVmQTJ3QVZpNUZUVTFkX1Q2R2ZwOG1FUDl2ZHJRNncwX2s1R2hSLVhIOXhWTkJJWjdtTWdFSkxVVTRqcnFYY2d6SVRJcVBNcGtQQjQyTlkwMlJ2OXhFczMzMXZkZlVOWnZGV3NGNE9faTJFYlcwX0pnUQ?oc=5" target="_blank">Retatrutide Delivers Unprecedented Weight Loss in Phase 3</a>  <font color="#6f6f6f">Medscape</font>

Read Full StoryMore like this
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Drug Discovery & Developmentgeneral

Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQbDJWQ2ZVVnZ0RUFBZE5CRjY5YmFRNTVFZFdwbkN0WHpsMUpPTTFmbTkyMXVHNFBIZE1nMWdtZWZaVHUzRHU1VnlLQUpBWTVwM2xfT3p3ZHBHRVJoOU5jZ3NzMmhJbFIxODFHbEM4WEl1UnFNRm9ZblltSFdpaklnRzktbEMtSExvS255NW1FV3l3R0sxRGplZkFiNEYwQktfNGl3?oc=5" target="_blank">Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial</a>  <font color="#6f6f6f">Drug Discovery & Development</font>

Read Full StoryMore like this
Novo Nordisk Phase II Data Validate Triple-Agonist Metabolic Targeting Approach
BioPharm Internationalgeneral

Novo Nordisk Phase II Data Validate Triple-Agonist Metabolic Targeting Approach

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOYm9mbVdRNDNUd3ZCVHFMakk2Z0l6bS1lNVczOG54VU1vMHNFTnJ0N3lVUlRHb1pWY1VpSHZVMGsyNU5tdU9LTTA0OWVQX3lUTVpJSkdFeEZYS215SF90ckFoaTBSc2h0RE9rVjRhT2tKSXBqSjh0Y1Z3S3FyRUtrblJvbVpBdEpHR2pqUWFiZ3F1aG52NmlRZUkzSEZZUkhKbk9GRXZpaWV1bFlRT2xrSUlLYk41NEczTnB5NkhrMA?oc=5" target="_blank">Novo Nordisk Phase II Data Validate Triple-Agonist Metabolic Targeting Approach</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer
The ASCO Postworld

Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxNLWlMZkJSM2dHbHMtYnNZcFZSQUdXNUZlUDhxRUNKM2hhR0dPZG1kVG51czJrVUdFWjN0LVo3R0otV3daTVlxU1dfY3FTYVBCc0lPMC1xQThZUTQ4U1I3OFVFNHFvZGl3U0tnTWN5SDVpRXpPU1hvRTAzcE1wLV9NUTRZQmI5V2FNRzRzbUlRU2pHelAtYURlZFVsa2N5VzgxakFmRE5PTDZobWR5UXNKOWUwaWJKR3ZlX0V2NWQ0YlRCMzd6Vmtia1F0aDNGQ2RNRnZzU1FFVFctUWN1R3AzaWh3cWlYZmJQeEE?oc=5" target="_blank">Use of Immune Checkpoint Inhibitors Under Study in High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
Naturegeneral

Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1ndVlyODZrb3ZTei1TYU9LVUU4UjZXNW1IVElGQTVuTTl2bGtZWklKUjZUNWsyeDZxQ2htWFo5Rzh4SXc4WmsyX0pDZU1SejM4QVpHeFYtckZpZTgwTWlF?oc=5" target="_blank">Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
What is triple-positive breast cancer? 6 insights
UT MD Andersongeneral

What is triple-positive breast cancer? 6 insights

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOdEIxUDhwb0oyX3ROM29EZHZtRzRYdkNoSXNPVnZKOUg2R2VDeVpaYWZscV92VGtWdk1NQUlMQUlIb01lSGh0LW91NUNYWDA0cFVwb2QzNmkyTk14VmE1Z2VRNGozNGlMTXNsRHlEWmpPWUZTdlZJMTBmTU82dWZTMkxlT1RJdkUzd0tJQUphQVJmUEJMaHNLQmMyT21BZlJnb0hITnhSWnN0Zw?oc=5" target="_blank">What is triple-positive breast cancer? 6 insights</a>  <font color="#6f6f6f">UT MD Anderson</font>

Read Full StoryMore like this
Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
Natureworld

Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9iOHhTakZuWVpHaDZKOE9yNjNBXzB6Mk8tVEtNb2xlbUtGaVA2SHBfLS1yQy1Gbm5OT3FlaVcwVXdVbHU0Nm1WWkxPVm9zSmplT083THVkczMxMDY5alIw?oc=5" target="_blank">Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech
BioSpacetech

Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMHFfRVQ4ejZDdFAxbXVESG5BaC04ZjR5VXFPZWx2VjJoSHFkU0g0NW5uSUk1bHdENlVDcUFjZXE2dlR0ZVRqNHh6WUJHZUhvU05SM181Ti1Uc3piWHNlQkFPS0cycEI1bUU3RjRoRkNjMURVeHpVUWF2RVhzLXFTN3kxWEszLVdaS2MtU3dtVS1Cd1laV09pdXVFXzZCdlRCOGlJMndLam1Xc1RiY1BWZzRJSzM0TGV3MFVQSg?oc=5" target="_blank">Novo Challenges Lilly With up to $2B Bet for Triple-G Obesity Drug From Chinese Biotech</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
"Triple hormone receptor a" — Live Google News Trends & Headlines